Press release:
March 6, 2012
Mitsubishi Tanabe Pharma Corporation
Daiichi Sankyo Co., Ltd.
Companies conclude joint sales agreement for two treatments for type 2 diabetes mellitus - MP-513 and TA-7284
Osaka and Tokyo, Japan (March 6, 2012) - Mitsubishi Tanabe Pharma Corporation (hereafter, Mitsubishi Tanabe Pharma; Head Office: Chuo-ku, Osaka; President and CEO: Michihiro Tsuchiya) and Daiichi Sankyo Co., Ltd., (hereafter, Daiichi Sankyo; Head Office: Chuo-ku, Tokyo; President and CEO: Joji Nakayama) have agreed to form a strategic sales alliance to conduct joint sales activities for DPP4 inhibitor, MP-513 (generic name: teneligliptin), and SGLT2 inhibitor, TA-7284 (generic name: canagliflozin), which are under development by Mitsubishi Tanabe Pharma in Japan for the treatment of type 2 diabetes mellitus.
MP-513, a DPP4 inhibitor and TA-7284, a SGLT2 inhibitor,
which were both discovered by Mitsubishi Tanabe Pharma, are
oral treatments for type 2 diabetes mellitus. MP-513 and
TA-7284 have different mechanisms of action. In Japan,
Mitsubishi Tanabe Pharma filed an NDA for MP-513 in August
2011, and TA-7284 is currently in phase 3 clinical trials
with plans calling for an NDA expected to be filed in
2013.
Mitsubishi Tanabe Pharma and Daiichi Sankyo will conduct
joint sales activities for these drugs under a one-brand,
two-channel framework. Moreover, the companies will implement
new types of joint sales activities, with detailed drug
product information provided through mutual visits to medical
institutions. In the diversifying market for diabetes
treatment agents, these activities will enable the companies
to build a dynamic, cooperative sales system. This system
will leverage the companies' combined marketing
capabilities, which will be among the strongest in Japan, and
facilitate the detailed, sufficient, yet rapid, provision of
accurate usage information and the proposal of
treatments.
Through this strategic alliance, Mitsubishi Tanabe Pharma and
Daiichi Sankyo will provide new treatment options for type 2
diabetes mellitus and support for patients dealing with
diabetes.
For more information about MP-513 and TA-7284, please see the
attachment.
For further information, please contact: Mitsubishi Tanabe
Pharma Corporation Corporate Communications Department
TEL